Despite higher sales, biotech drugmaker Amgen's first-quarter profit fell 25 percent as production and research costs rose sharply, while the year-ago quarter enjoyed a tax benefit. The company badly missed ...
Health clinics that can provide primary care for low-income patients may ease the financial burden on both hospitals and insurance companies while improving patient health, researchers have concluded.
To help rein in massive health care spending, a new RAND study concludes that U.S. policy makers should urgently find ways to incentivize pharmaceutical companies and device makers to develop products that produce more value.
A federal judge has blocked Massachusetts from banning the powerful new painkiller Zohydro.
A new government report says the Affordable Care Act's health insurance subsidies will cost a little less than previously thought.
As hundreds of thousands of diabetics get health coverage under the federal law, insurance companies are aggressively targeting this glut of new patients.
The prospect of four new cancer medicines becoming a reality for patients has taken a huge step forward with the announcement of a £34M investment by a European private biotech company in University research.
(HealthDay)—Researchers report that an experimental drug has cured more than 95 percent of patients infected with hepatitis C, including some who failed other treatments.
As a virologist, I am often asked when science will come up with a solution to stop deadly viruses, such as the Ebola outbreak in Guinea. With collaborators I have helped to design and/or test over a hundred potentially ...
The Japanese unit of major drugmaker Janssen Pharmaceuticals says 17 people have died after being injected with its drug to treat schizophrenia since it was launched in Japan last November.
The Food and Drug Administration is taking steps to ensure that shoppers who buy honey are getting the real deal.
As the ranks of heroin users rise in the U.S., increasing numbers of addicts are looking for help but are failing to find it—because there are no beds in packed facilities, treatment is hugely expensive ...
About 40 percent of pharmaceutical company boards of directors examined had at least one member who held a leadership position at an academic medical center, with annual compensation for these positions averaging approximately ...
It's not too late to get covered. A few routes remain open for those who missed the health care law's enrollment deadline Monday.
The Supreme Court is wading into a patent dispute between rival pharmaceutical companies over a multiple sclerosis treatment.